Cyclosporin A inhibits mitochondrial biogenesis in Hep G2 cells

Area of Science:

• Cellular Biology
• Mitochondrial Biology
• Pharmacology

Background:

• Mitochondrial biogenesis dysregulation is linked to various diseases, including liver conditions.
• Cyclosporine A (CsA), an immunosuppressant, is known to induce mitochondrial dysfunction, but the precise mechanisms are unclear.

Purpose of the Study:

• To elucidate the cellular mechanisms by which CsA causes mitochondrial dysfunction.
• To investigate the role of PGC-1α and CREB in CsA-induced mitochondrial impairment.

Main Methods:

• HepG2 cells were treated with CsA to assess effects on PGC-1α, NRF1, and TFAM expression.
• Mitochondrial DNA (mtDNA)/nuclear DNA (nDNA) ratio, mitochondrial mass, ATP production, and cytochrome c oxidase activity were measured.
• Over-expression of PGC-1α was used to evaluate its protective effects against CsA.

Main Results:

• CsA significantly reduced PGC-1α mRNA and protein expression in HepG2 cells.
• Expression of PGC-1α target genes, NRF1 and TFAM, was also decreased by CsA.
• CsA treatment led to significant reductions in mtDNA/nDNA ratio, mitochondrial mass, ATP production, and cytochrome c oxidase activity.
• Over-expression of PGC-1α mitigated the negative impact of CsA on mitochondrial biogenesis.
• CREB was identified as a key mediator in the inhibitory effects of CsA on mitochondrial biogenesis.

Conclusions:

• CsA impairs mitochondrial biogenesis through the downregulation of PGC-1α and its downstream targets.
• CREB plays a crucial role in mediating CsA's inhibitory effects on mitochondrial function.
• PGC-1α is a potential therapeutic target for counteracting CsA-induced mitochondrial dysfunction.